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S U M M A R Y
Objectives: To prospectively evaluate the performance of two matrix-assisted laser desorption/ionization
time-of-ﬂight mass spectrometry systems (MALDI-TOF MS) for the identiﬁcation of clinically signiﬁcant
yeast isolates compared to the VITEK 2 system.
Methods: One hundred and eighty-eight consecutive yeast isolates were analyzed by Bruker Biotyper
and VITEK MS. The results were compared with the conventional VITEK 2 yeast identiﬁcation system.
Discrepant results were resolved by direct sequencing of rDNA.
Results: Accurate identiﬁcation by VITEK 2, VITEK MS, and Bruker Biotyper MS was 94.1% (177/188),
93.0% (175/188), and 92.6% (174/188), respectively. Three isolates were not identiﬁed by VITEK MS,
while nine Candida orthopsilosis were misidentiﬁed as Candida parapsilosis, as this species is not present
in its database. Eleven isolates were not identiﬁed or were wrongly identiﬁed by Bruker Biotyper and
although another 14 were correctly identiﬁed, the score was unreliable at <1.7.
Conclusion: The overall accuracy of rapid MALDI-TOF MS systems was essentially comparable to that of
the conventional VITEK 2 yeast identiﬁcation system. However, future expansion of the databases may
further improve the outcome and accuracy of identiﬁcation of yeast species.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Invasive fungal infections due to opportunistic pathogens cause
signiﬁcant mortality and morbidity, especially in immunocompro-
mised and critically ill patients.1,2 In the USA, Candida species are
the fourth most common cause of healthcare-associated blood
stream infection, with an associated mortality rate of 39.2%.3,4
Although Candida albicans is the most commonly identiﬁed
pathogenic yeast species, other non-albicans Candida species and
species of other genera have also been reported as causative agents
of invasive infections.4 The rapid identiﬁcation of pathogenic
species is helpful to start timely and effective antifungal therapy.
This rapid identiﬁcation will narrow the spectrum of therapeutic
options, conceivably prevent treatment with toxic antifungal
agents, improve the outcome, and reduce costs.4 Using conven-
tional methods to identify yeasts takes 2–5 days. These phenotypic* Corresponding author. Tel.: +965 2463 6781; fax: +965 2533 2719.
E-mail address: wjamal@hsc.edu.kw (W.Y. Jamal).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).methods may not identify or may misidentify some yeast species.5
Molecular methods, e.g., 18S rDNA or internal transcribed spacer
(ITS) region sequencing, identify yeasts to the species level but are
time-consuming, tedious, technically demanding, and not available
in many diagnostic microbiology laboratories.6,7
Due to the above limitations, recent studies had focused on
alternative techniques to rapidly identify yeasts, such as matrix-
assisted laser desorption/ionization time-of-ﬂight mass spectrome-
try (MALDI-TOF MS).8–13 The aim of this study was to evaluate
the performance of two MALDI-TOF MS systems for the rapid
identiﬁcation of clinically relevant yeast isolates to the species level
and to compare the results with the routine conventional methods.
2. Materials and methods
2.1. Sample collection
A total of 188 clinically relevant fungal isolates were obtained
during 1 year of routine laboratory processing of clinical specimens
in the Microbiology Unit, Mubarak Al Kabir Hospital, Kuwait. Theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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criteria. Duplicate isolates from the same patient were excluded.
The isolates were obtained from blood culture, bronchoalveolar
lavage, cerebrospinal ﬂuid, urine, wound, and high vaginal and
endocervical swabs. The isolates were cultured on Sabouraud
dextrose agar (SDA, Oxoid, Basingstoke, Hampshire, UK) and
incubated for 48–96 h at 30 8C.
2.2. Identiﬁcation by VITEK 2
The identiﬁcation of the clinical yeast isolates was initially
achieved by VITEK 2 system (bioMe´rieux) using YST ID (Card No.
21343). When necessary, one or more tests were also performed,
e.g., morphology on SDA, germ tube test for Candida species, and
urease assimilation test for Cryptococcus species (Becton, Dick-
inson and Company, Sparks, MD, USA).
2.3. Protein extraction
Prior to MALDI-TOF MS analyses, a single colony from a fresh
culture was suspended in 1 ml of 70% ethanol, brieﬂy vortexed, and
centrifuged at 13 000 g for 2 min. The supernatant was removed,
the pellet quickly spun again, and the residual ethanol removed.
The pellet was re-suspended in 50 ml of 70% formic acid (Fluka,
USA) and 50 ml acetonitrile (Fluka). The sample was vortexed
brieﬂy and the mixture centrifuged for 2 min at 3000 g.
2.4. MALDI-TOF Bruker MS (Bruker Biotyper; Bruker Daltonics,
Bremen, Germany)
One microliter of sample suspension was spotted onto a 96-
spot reusable stainless steel target plate (Bruker Daltonics) in
duplicate, allowed to evaporate, and dried at 37 8C on a plate
warmer; this was then overlaid with 2 ml of matrix solution
(Bruker Daltonics) and air-dried. The loaded plate was applied to
the instrument in accordance with the manufacturer’s instructions
and analyzed by Bruker Microﬂex LT system using FlexControl
software (version 3.3). The spectrum of each isolate was compared
with those in the database and the identiﬁcation was provided by
score of reliability. Identiﬁcation was provided with accompanying
scores as per the manufacturer’s schemes: <1.7 = no reliable
identity; 1.7 and <2.0 = identity at genus level; 2.0 = identity at
species level.
2.5. MALDI-TOF VITEK MS (VITEK MS; bioMe´rieux, Marcy l’Etoile,
France)
The suspension was tested in duplicate on the MALDI plate.
One microliter of the extracted supernatant was transferred
onto an individual spot on the 48-well VITEK MS disposable
target slide. Each spot was covered with 1 ml ready-to-use
VITEK MS HCCH matrix (bioMe´rieux) and air-dried. The loaded
slides were inserted into the VITEK MS machine. The VITEK mass
spectrometer was used to generate spectra of the yeast
suspension; Biotyper software (version 2.0) was used to analyze
the results. Microbial identiﬁcation was achieved by analyzing
the spectra with the VITEK MS database. The peaks from these
spectra were compared with the characteristic pattern for the
species, genus, or family of the microorganism, leading to
identiﬁcation. The results were evaluated according to a colored
index: green means 90% identity, yellow 85–89.9% identity,
and white <85% identity. All of the identiﬁcations to the genus
or species level fell into the green zone, with a score of >90%
considered reliable. Scores between 85% and 90% were consid-
ered acceptable identiﬁcation. A cut-off of 90% was chosen for
the VITEK MS.2.6. Quality control
Escherichia coli ATCC 8739 was included as a positive control in
each run in both MALDI-TOF MS systems, in accordance with the
manufacturer’s recommendations. Uninoculated matrix was
included in each run as a negative control. For standardization
purposes, positive controls were included in each run (Candida
albicans CBS 5314, Candida albicans CBS 1893, and Candida glabrata
CBS 7904).
2.7. DNA isolation and sequencing
DNA was extracted from colonies of yeast isolates and grown on
SDA plates, using the QIAamp DNA Kit (Qiagen, Hilden, Germany)
as per the manufacturer’s instructions. PCR and sequencing of the
ITS region (including ITS-1, 5.8S rRNA, and ITS-2) and D1/D2
domains of the large subunit (LSU) of rDNA were performed as
described previously.14 The sequences obtained were compared
with data available in the GenBank database using nucleotide Basic
Local Alignment Search Tool (BLASTn; http://www.ncbi.nlm.nih.-
gov/BLAST/Blast.cgi?). A threshold of 99% sequence identity was
used for identiﬁcation at the species level.
2.8. Criteria for ﬁnal species identiﬁcation
The ﬁnal identiﬁcation was as follows: accurate identiﬁcation of
the species was conﬁrmed if all three methods yielded the same
species identity. When discrepant results were observed for the
three methods, or when only two of the three methods yielded
different identiﬁcation, molecular identiﬁcation based on direct
DNA sequencing was considered as the gold standard for ﬁnal
species identity.
3. Results
3.1. Final identiﬁcation of the isolates
For 163 of 188 (86.7%) isolates, the use of the conventional
VITEK 2 method and the two MALDI-TOF systems resulted in
accurate identiﬁcation of 48 Candida parapsilosis, 30 Candida
tropicalis, 27 C. glabrata, 27 C. albicans, 15 Candida krusei, 2 Candida
dubliniensis, 4 Candida lusitaniae, 2 Candida kefyr, 4 Geotrichum
capitatum, 2 Candida intermedia, 1 Candida guilliermondii, and 1
Trichosporon asahii (Table 1). For the remaining 25 (13.3%) isolates,
the ﬁnal identiﬁcation was done via direct DNA sequencing
(Table 2). The DNA sequences have been submitted to the
European Molecular Biology Laboratory (EMBL) under accession
numbers HG970734 to HG970744.
3.2. Performance of each identiﬁcation method
Discrepancies in the errors in the three systems of identiﬁcation
are given in Table 1.
The VITEK 2 system and other conventional tests could
accurately identify 177 of 188 (94.0%) isolates. They did not
identify one C. guilliermondii and misidentiﬁed one Pichia veronae
isolate as Candida freyschussii and nine Candida orthopsilosis as C.
parapsilosis.
As shown in Table 1, VITEK MS was able to accurately identify
175 of 188 (93.1%) isolates. It misidentiﬁed nine C. orthopsilosis as
C. parapsilosis because it was not present in its database. It failed to
identify one Cryptococcus neoformans, one Saccharomyces cerevi-
siae, and one Rhodotorula mucilaginosa isolate. It misidentiﬁed one
P. veronae isolate as C. freyschussii.
The Bruker Biotyper could identify 174 of 188 (92.6%) isolates,
but accurate identiﬁcation with a high score was achieved for only
Table 2
Discrepancies and error in the MALDI-TOF (Bruker MS and VITEK MS) for identiﬁcation (ID) of yeast
Species (n) Biotyper ID VITEK MS ID Sequence
identity (%)
Remarks
Candida orthopsilosis (9) 6 score <1.7; 3 Candida parapsilosis C. parapsilosis >99 VITEK MS: not in database
Candida tropicalis (3) Score <1.7 Correct ID >99 Biotyper: unacceptable ID
Candida glabrata (1) Score <1.7 Correct ID >99 Biotyper: unacceptable ID
Candida dubliniensis (4) Score <1.7 Correct ID >99 Biotyper: unacceptable ID
Candida kefyr (2) Pseudomonas, Staphylococcus Correct ID >99 Biotyper: wrong ID
Candida famata (1) Debaryomyces Correct ID >99 Biotyper: wrong ID
Candida guilliermondii (1) Nocardia spp Correct ID >99 Biotyper: wrong ID
Pichia veronae (1) Pseudomonas Candida freyschussii >99 Biotyper: wrong ID
Saccharomyces cerevisiae (1) 1 1 >99 No ID by both systems
Cryptococcus neoformans (1) 1 1 >99 No ID by both system
Rhodotorula mucilaginosa (1) 1 1 >99 No ID by both system
Table 1
List of species and results of identiﬁcation (ID) using Biotyper and VITEK MS and conventional ID (VITEK 2)
Species (n) Conventional ID Biotyper ID VITEK MS ID
Correct No ID False Correct No ID False Correct No ID False
Candida parapsilosis (48) 48 0 0 48 0 0 48 0 0
Candida orthopsilosis (9) 0 0 9 0 6 (<1.7) 3 0 0 9
Candida tropicalis (33) 33 0 0 30 3 (<1.7) 0 33 0 0
Candida glabrata (28) 28 0 0 27 1 (<1.7) 0 28 0 0
Candida albicans (27) 27 0 0 27 0 0 27 0 0
Candida krusei (15) 15 0 0 15 0 0 15 0 0
Candida dubliniensis (6) 6 0 0 2 4 (<1.7) 0 6 0 0
Candida famata (1) 1 0 0 0 0 1 1 0 0
Candida lusitaniae (4) 4 0 0 4 0 0 4 0 0
Candida kefyr (4) 4 0 0 2 0 2 4 0 0
Geotrichum capitatum (4) 4 0 0 4 0 0 4 0 0
Candida intermedia (2) 2 0 0 2 0 0 2 0 0
Candida guilliermondii (2) 1 1 0 1 0 1 2 0 0
Pichia veronae (1) 0 0 1 0 0 1 0 0 1
Trichosporon asahii (1) 1 0 0 1 0 0 1 0 0
Saccharomyces cerevisiae (1) 1 0 0 0 1 0 0 1 0
Cryptococcus neoformans (1) 1 0 0 0 1 0 0 1 0
Rhodotorula mucilaginosa (1) 1 0 0 0 1 0 0 1 0
Total (188) (%) 177 (94.1) 1 10 (5.3) 163 (86.7) 17 (9.0) 8 (4.3) 175 (93.1) 3 (1.5) 10 (5.3)
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neoformans, one S. cerevisiae, and one R. mucilaginosa isolate. One
Candida famata was misidentiﬁed as Debaryomyces spp, two C. kefyr
were misidentiﬁed as Pseudomonas spp and Staphylococcus spp, one
C. guilliermondii was wrongly identiﬁed as Nocardia spp, and one P.
veronae as Pseudomonas spp. Three of nine C. orthopsilosis were
identiﬁed as C. parapsilosis; the identiﬁcation of the remaining C.
orthopsilosis was with an unreliable score of <1.7. Similarly, three
C. tropicalis, four C. dubliniensis, and one C. glabrata were also
identiﬁed correctly, but with an unreliable score of <1.7.
4. Discussion
In this study, correct identiﬁcation by morphological and
conventional tests (VITEK 2) was achieved for 94.1% of the isolates,
a ﬁnding higher than previously reported: 84% (via API ID 32 C,
bioMe´rieux),15 75% (via API ID 32 C or Rapid ID yeast),11 91.5% (via
API ID 32 C),16 and 77% (via API).13 However, our report is
concordant with a previous report by Valenza et al., who reported
that 93.7% of yeasts can be identiﬁed satisfactorily by VITEK 2 with
simple additional tests.17
MALDI-TOF MS systems have recently been developed and
implemented in diagnostic microbiology laboratories for species-
speciﬁc identiﬁcation of bacterial and fungal pathogens due to
their rapidity, minimum hands-on time, efﬁcacy, and overall cost-
effectiveness. The MALDI-TOF MS systems provide objective
results for the identiﬁcation of most yeast species and may alsohelp to standardize laboratory tests, which are crucial for
strengthening the laboratory services in limited-resource areas.
However, their optimal use is dependent on the panel of bacterial
and yeast reference strains included in their databases. For these
reasons, the accuracy of the MALDI-TOF MS systems in the
identiﬁcation of yeasts has varied considerably as compared to the
conventional techniques in some studies. For instance, the
accuracy of the Bruker Biotyper has been found to vary from
84% to 99%,12,15,16 while the accuracy of the VITEK MS system has
been found to be somewhat lower (84.3–95%)18–20 compared to
the conventional techniques.
In this study, the identiﬁcation rate was 93.0% for the VITEK MS
and 92.6% for the Bruker Biotyper. These ﬁndings are slightly lower
than those reported in recent studies in which the identiﬁcation
rates for yeast have typically ranged between 97.6% and
98.3%.8,16,21 Other studies have reported a lower rate of
identiﬁcation of yeasts in the range of 84–89.8% without major
errors at the species level via Bruker Biotyper11,13,19 and 84.3–
87.2% via VITEK MS.18,19
The VITEK MS failed to identify nine C. orthopsilosis isolates, as
this species is not included in its database. Some studies have
either included very few isolates (e.g., C. orthopsilosis) that are not
represented in the MALDI-TOF MS database or excluded them
while calculating accurate identiﬁcation.9,22 If the nine C.
orthopsilosis isolates are excluded, the accuracy of VITEK MS in
the correct identiﬁcation of yeasts in the present study increases to
97.8%, with only one misidentiﬁcation.
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but accurate identiﬁcation (score of 2.0) was achieved for only
163 of 188 (86.7%) isolates. Six C. orthopsilosis, three C. tropicalis,
four C. dubliniensis, and one C. glabrata were identiﬁed with an
unreliable score of <1.7. In some studies, repeat testing or extra
extraction steps were required for several isolates by Bruker
Biotyper to obtain a spectral score of >2.0.9,12,22 We did not ﬁnd
repetition of these steps necessary, as it would involve additional
time and resources and would affect routine ﬂow in the clinical
microbiology laboratory. The lower scores for some isolates might
presumably be because we used SDA, which has been shown
previously to perform less optimally compared to brain–heart
infusion agar or inhibitory mold agar media, although it is more
economical and is most widely used in routine microbiology
laboratories.22,23 Some investigators have argued for lowering the
threshold score for the Bruker Biotyper to 1.8 or even to 1.7
without affecting accurate identiﬁcation.9,12,22 Our results also
show that the cut-off for the Bruker Biotyper can safely be lowered
to 1.7 without affecting the accuracy of species-speciﬁc identiﬁca-
tion and this will diminish the need for additional extraction steps
during MALDI-TOF MS analyses.
In conclusion, MALDI-TOF MS methods provide a standardized
working protocol for the identiﬁcation of yeasts from clinical
specimens. The short turn-around time and expandability of the
database demonstrate that this is a suitable ﬁrst-line test for the
identiﬁcation of yeasts in the routine clinical microbiology
laboratory.
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